Trial Profile

A Phase I Study of Safety and Pharmacokinetics of LP002 (a Humanized Monoclonal Antibody Targeting PD-L1) in Patients With Malignant Digestive System Neoplasms

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LP 002-Lepu Biopharma (Primary) ; Cisplatin; Fluorouracil; OH 2
Indications Adenocarcinoma; Carcinoma; Digestive system neoplasms; Gastric cancer; Neuroendocrine tumours; Oesophageal cancer; Solid tumours
Focus Adverse reactions
Sponsors Taizhou HoudeAoke Biomedical

Most Recent Events

07 Jun 2022 Results (n=30) assessing safety and pathological response of gastroesophageal cancer pts receiving LP002, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
18 Feb 2021 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com